13D Filing: Aisling Capital III LP and Transenterix Inc. (TRXC)

Page 9 of 12

Page 9 of 12 – SEC Filing

CUSIP No. 89366M102
SCHEDULE 13D/A
Page 9 of 12

Item 4.
Purpose of Transaction.
Item 4 is hereby amended and supplemented as follows:
Reporting Persons may acquire or dispose of additional securities or sell securities of the Issuer from time to time in the market or in private transactions. As described in Item 3 of this Schedule 13D, as amended, Aisling holds Series B Warrants to purchase an aggregate of 1,500,000 shares of Common Stock.
Item 5.
Interest in Securities of the Issuer.
Items 5(a), (b) and (c) are amended and restated in their entirety as follows:
(a) The aggregate percentage of shares of Common Stock reported as owned by each Reporting Person is based on an 199,241,522 shares of Common Stock issued and outstanding as of November 3, 2017, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities Exchange Commission (the “SEC”) on November 9, 2017. Based on calculations made in accordance with Rule 13d 3(d), the Reporting Persons beneficially own in the aggregate 11,490,831 shares of Common Stock, representing 5.8% of the total issued and outstanding shares of Common Stock.
 
Aisling Capital III, LP
Aisling Capital Partners III, LP
Aisling Capital Partners III LLC
Common
Stock
Amount beneficially owned:
11,490,831
Percent of class:
(i) Sole voting power
5.8
%
(ii) Shared voting power
0
(iii) Sole dispositive power
5.8
%
(iv) Shared dispositive power
0
 
Steve Elms
Dennis Purcell
Andrew Schiff
Common
Stock
Amount beneficially owned:
11,490,831
Percent of class:
(i) Sole voting power
0
(ii) Shared voting power
5.8
%
(iii) Sole dispositive power
0
(iv) Shared dispositive power
5.8
%

Follow Asensus Surgical Inc. (NYSEMKT:ASXC)

Page 9 of 12